Strain-specific humoral response to a polymorphic malaria vaccine

Area of Science:

• Immunology
• Parasitology
• Vaccinology

Background:

• Plasmodium falciparum merozoite surface protein 2 (MSP2) is a polymorphic antigen and a component of the Combination B malaria vaccine.
• Understanding the immune response to MSP2 variants is crucial for developing effective malaria vaccines.

Purpose of the Study:

• To determine if vaccination with the 3D7 MSP2 variant elicits a strain-specific or conserved immune response.
• To evaluate the immunogenicity of different MSP2 domains.

Main Methods:

• A phase I/IIb trial vaccinated 120 children with Combination B vaccine.
• Antibody titers against individual MSP2 domains were measured using enzyme-linked immunosorbent assay (ELISA) pre- and post-vaccination.
• Comparison of antibody responses against 3D7 and FC27 MSP2 family-specific domains and repeats.

Main Results:

• Vaccination with 3D7 MSP2 induced a significant strain-specific humoral response targeting the repetitive, family-specific region.
• Conserved N- and C-terminal domains of MSP2 were not immunogenic.
• A trend towards increased antibodies against the FC27 family-specific domain was observed, but not against FC27-type repeats.

Conclusions:

• A single MSP2 variant vaccine primarily induces a strain-specific immune response.
• This strain-specificity may explain the selective pressure on breakthrough parasite genotypes observed with Combination B.
• Including both 3D7 and FC27 family-specific MSP2 domains is recommended for improved malaria vaccine formulations.